Results 41 to 50 of about 29,210 (297)

Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study

Journal of Clinical Oncology, 2023
PURPOSE To present primary and final analyses from the randomized, double-blind, placebo-controlled, phase III iNTEGRATE study, which evaluated the safety and efficacy of ibrutinib with prednisone in previously untreated patients with chronic graft ...
D. Miklos, M. Abu Zaid, J. Cooney, J. Albring, M. Flowers, A. Skarbnik, I. Yakoub-Agha, B. Ko, B. Bruno, E. Waller, J. Yared, S. Sohn, C. Bulabois, T. Teshima, D. Jacobsohn, H. Greinix, A. Mokatrin, Yihua Lee, J. Wahlstrom, L. Styles, G. Socié   +20 more
semanticscholar   +1 more source

Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576

Advances in Hematology, 2022
Ibrutinib-based therapies are costly and require continuous administration. We hypothesized combining BTK inhibition with anti-CD20 monoclonal antibodies would yield deep remissions allowing discontinuation.
Januario E. Castro, Paula A. Lengerke-Diaz, Juliana Velez Lujan, Michael Y. Choi, Eider F. Moreno-Cortes, Jose V. Forero, Juan Esteban Garcia-Robledo, Chaja Jacobs, Colin McCarthy, Alaina Heinen, Carlos I. Amaya-Chanaga, Thomas J. Kipps   +11 more
doaj   +1 more source

Ibrutinib Inhibits Angiogenesis and Tumorigenesis in a BTK-Independent Manner

Pharmaceutics, 2022
BTK inhibitor (BTKi) Ibrutinib carries an increased bleeding risk compared to more selective BTKis Acalabrutinib and Zanubrutinib, however, its impact on vascular endothelium remains unknown.
Jia Liu, Zhuojun Liu, Jing Zhang, Xiaofang Chen, Junge Chen, Linlin Sui, Jian Yu   +6 more
doaj   +1 more source

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.

New England Journal of Medicine, 2022
BACKGROUND Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma ...
Michael L. Wang, W. Jurczak, M. Jerkeman, J. Trotman, P. Zinzani, D. Belada, C. Boccomini, I. Flinn, P. Giri, A. Goy, P. Hamlin, O. Hermine, J. Hernández‐Rivas, X. Hong, S. Kim, D. Lewis, Y. Mishima, M. Özcan, G. Perini, C. Pocock, Yuqin Song, S. Spurgeon, J. Storring, J. Walewski, Jun Zhu, Rui Qin, T. Henninger, S. Deshpande, A. Howes, S. le Gouill, M. Dreyling   +30 more
semanticscholar   +1 more source

Choosing ibrutinib wisely [PDF]

Blood, 2018
In this issue of Blood , Bartlett et al share their experience with the use of ibrutinib in patients with relapsed or refractory follicular lymphoma (FL ...
openaire   +3 more sources

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Journal for ImmunoTherapy of Cancer, 2023
Background In preclinical studies of pancreatic ductal adenocarcinoma (PDAC), ibrutinib improved the antitumor efficacy of the standard of care chemotherapy.
Li Zhang, Matthew Crocker, Lawrence Fong, Lisa M Coussens, Charles D Lopez, Shamilene Sivagnanam, Meenal Sinha, Brandon Chen, Jaqueline Marquez, Alexander Cheung, Whitney Tamaki, Jacob Stultz, Kendra Todd, Courtney Betts, Madeline J Griffith, Isabelle Solman, Eric Liu, Denise Pener, Anne Fahlman, Erin Taber, Kimberly Lerner, Brindha Rajagopalan, Clarisha Ware, Mark Bridge, Johnson Vo, Hannah Dragomanovich, Julie Sudduth-Klinger, Gina Vaccaro, Margaret Tempero   +28 more
doaj   +1 more source

Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia

Clinical Cancer Research, 2023
Purpose: The CAPTIVATE study investigated first-line ibrutinib plus venetoclax for chronic lymphocytic leukemia in 2 cohorts: minimal residual disease (MRD)-guided randomized discontinuation (MRD cohort) and Fixed Duration (FD cohort). We report outcomes
J. Allan, I. Flinn, T. Siddiqi, P. Ghia, C. Tam, T. Kipps, P. Barr, Anna Elinder Camburn, A. Tedeschi, X. Badoux, R. Jacobs, B. Kuss, L. Trentin, Cathy Zhou, A. Szoke, C. Abbazio, W. Wierda   +16 more
semanticscholar   +1 more source

A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib

Molecules, 2022
Ibrutinib (IBR) is an oral anticancer medication that inhibits Bruton tyrosine kinase irreversibly. Due to the high risk of adverse effects and its pharmacokinetic variability, the safe and effective use of IBR is expected to be facilitated by precision dosing. Delivering suitable clinical laboratory information on IBR is a prerequisite of constructing
Gellért Balázs Karvaly, István Vincze, Alexandra Balogh, Zoltán Köllő, Csaba Bödör, Barna Vásárhelyi   +5 more
openaire   +3 more sources

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

eJHaem, 2021
ROR1 – a receptor tyrosine kinase – is overexpressed in CLL. Ibrutinib, a Bruton's tyrosine kinase inhibitor, is clinically effective in CLL but patients may develop resistance. We evaluated the effect of an ROR1 inhibitor, KAN0441571C, in CLL cells from
Amineh Ghaderi, Mohammad‐Ali Okhovat, Layung Sekar Sih Wikanthi, Ann Svensson, Marzia Palma, Johan Schultz, Thomas Olin, Anders Österborg, Håkan Mellstedt, Mohammad Hojjat‐Farsangi   +9 more
doaj   +1 more source

Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia

Blood, 2023
Key Points • The combination of ibrutinib and venetoclax induced deep and durable responses in treatment-naïve patients with Waldenström macroglobulinemia.• Planned study therapy was stopped early due to a higher-than-expected occurrence of ventricular ...
J. J. Castillo, A. Branagan, David Sermer, C. Flynn, K. Meid, M. Little, Katherine Stockman, Timothy P. White, A. Canning, M. L. Guerrera, A. Kofides, Shirong Liu, Xia Liu, Kris Richardson, Nicholas Tsakmaklis, C. Patterson, Z. Hunter, S. Treon, S. Sarosiek   +18 more
semanticscholar   +1 more source